Health
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
Publication: STAT
Author: Ed Silverman
Source published: 01/10/2026, 13:26:58 UTC
Briefing created: 02/10/2026, 01:49:17 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 01/10/2026, 22:22:24 UTC.
Briefings
The Trump administration released a final rule to lower Medicare drug prices, but it only applies to four companies and achieves only 96% of the initial savings target. A separate pilot program, GLOBE, is mandatory for efficient pricing, while another pilot, GUARD, remains proposed. An investigational Eli Lilly therapy combining Zepbound with eloralintide showed significant weight loss in a mid-stage study, yet high discontinuation rates may affect tolerability. The study involved 48 weeks of data with participants losing an average of 23.3% of their weight on the highest dose combination therapy.
Key points
- The Trump administration's final rule applies to only four companies and achieves 96% of the initial savings target for Medicare drug prices.
- An investigational Eli Lilly therapy combining Zepbound with eloralintide showed significant weight loss in a mid-stage study, though high discontinuation rates may affect tolerability.
Context and limitations
Data covers a mid-stage study with 48 weeks of data; specific participant numbers and full study outcomes are not detailed in the provided evidence.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 02/10/2026, 01:49:17 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeihhgxpkra76l2rfeoecjogxiz2akqsskb7doadzqyaaqju6on5nq4